{"id":"interferon-beta-1a-prefilled-syringe","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site reactions"},{"rate":"30-40","effect":"Flu-like symptoms (fever, chills, myalgia)"},{"rate":"25-35","effect":"Headache"},{"rate":"20-30","effect":"Fatigue"},{"rate":"5-10","effect":"Depression"},{"rate":"10-15","effect":"Elevated liver enzymes"},{"rate":"5-10","effect":"Leukopenia"}]},"_chembl":{"chemblId":"CHEMBL1201562","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon Beta-1A is a recombinant cytokine that engages type I interferon receptors (IFNAR1 and IFNAR2), triggering JAK-STAT signaling cascades that enhance natural killer cell activity, increase antigen presentation, and reduce pro-inflammatory cytokine production. This results in immunomodulation and reduced disease activity in autoimmune conditions, particularly multiple sclerosis.","oneSentence":"Interferon Beta-1A binds to type I interferon receptors on cell surfaces to activate antiviral and immunomodulatory pathways.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:27.227Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"},{"name":"Secondary progressive multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT04315948","phase":"PHASE3","title":"Trial of Treatments for COVID-19 in Hospitalized Adults","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2020-03-22","conditions":"Corona Virus Infection","enrollment":1552},{"nctId":"NCT06510426","phase":"PHASE2","title":"Early Interferon-beta Treatment for West-Nile Virus Infection","status":"RECRUITING","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2024-07-14","conditions":"West Nile Virus, West Nile Fever Encephalitis, West Nile Fever Myelitis","enrollment":100},{"nctId":"NCT05242133","phase":"PHASE3","title":"Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2017-12-20","conditions":"Relapsing Remitting Multiple Sclerosis (RRMS)","enrollment":168},{"nctId":"NCT04492475","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial 3 (ACTT-3)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-05","conditions":"COVID-19","enrollment":969},{"nctId":"NCT03614715","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a)","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2017-11-27","conditions":"Bioequivalence, Healthy","enrollment":40},{"nctId":"NCT00828204","phase":"PHASE3","title":"Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects","status":"COMPLETED","sponsor":"Biogen","startDate":"2009-01","conditions":"Multiple Sclerosis","enrollment":95},{"nctId":"NCT00958009","phase":"PHASE3","title":"The Multicenter, Open-label, Single-use Autoinjector Convenience Study","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2009-10","conditions":"Multiple Sclerosis","enrollment":109},{"nctId":"NCT00811395","phase":"PHASE2","title":"Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Multiple Sclerosis","enrollment":182}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CinnoVex®"],"phase":"phase_3","status":"active","brandName":"Interferon Beta-1A Prefilled Syringe","genericName":"Interferon Beta-1A Prefilled Syringe","companyName":"Cinnagen","companyId":"cinnagen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Interferon Beta-1A Prefilled Syringe is used to treat Multiple Sclerosis, according to ClinicalTrials.gov. It is also being studied as a potential treatment for West Nile Virus infection, specifically West Nile Fever Encephalitis, West Nile Fever Myelitis, and West Nile Fever With Other Complications, as part of the \"Early Interferon-beta Treatment for West-Nile Virus Infection\" clinical trial.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}